Inflammatory chemokines are induced by the CCR5 ligands and

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2 ohm20 #126494
473
Quote:
Inflammatory chemokines are induced by the CCR5 ligands and activate STAT3 which flips macrophages to M2. The inflammatory stage (M1 macrophages) is what causes the M2 macrophages to be needed for repair. High levels of M1 macrophages causing excessive apoptosis, bad. High levels of M2 macrophages causing excess collagen deposition and extracellular matrix, even worse.


So if Inflammation is what flips Macrophages from M1 to M2, and if the M2 stage of excess collagen deposition is so much more so Inflammatory, where do the Macrophages go from there?

I guess you are in agreement that the laying down of fibrosis, that is both fibrogenesis as well as the resorption of fiber are both metabolized by M2 Macrophages. Am I right in thinking that any kind of metabolism of fiber, be it fibrogenesis or fiber resorption, are both accomplished by M2 macrophages?

But according to the study, Fibrogenesis is what leads to an increase in CCL3 and since by the definition of CCL3, an upregulation of CCL3 would happen in M1, then whenever CCL3 is elevated, the Macrophages would be operating in M1, even though Fibrogenesis happens in M2 according to the study. Could the study be wrong?


Quote:

Here's where the magic happens. Leronlimab knocks down the inflammatory chemokines disrupting the PI3K/AKT/mTORc/ STAT3 pathway and reverting macrophages to M1. The M1 macrophages would ordinarily induce a high inflammatory state, cell death and an even higher inflammatory state. But CCR5 blockade by leronlimab keeps that high inflammatory state from happening.

So leronlimab reduces the inflammation and reduces the M2 macrophages from creating fibrosis.


So then, you're saying that by adding LRM, even to the point of 100% RO, this should flip all the Macrophages to M1. Now, because it is Leronlimab and not RANTES or another chemokine, inflammation should be held at a minimum.

If we look at the Heat Map and you look at the horizontal lines of both INF gamma as well as CCL3, (Macrophage Inflammatory Protein 1 Alpha MIP1 alpha), you will see that these 2 look identical and when elevated, would point towards being in M1. Also, if you look at IL-4 which would be increased in M2, it almost looks like the opposite of INF gamma and CCL3.

Therefore, the increased presence of both INF gamma and CCL3 along with the reduced presence of IL-4 would point to being in M1 mode. And the opposite is true, the reduced presence of both INF gamma and CCL3 coinciding with the increased presence of IL-4 would point to being in M2 mode.

For the most part this correlates with the Heat Map, except for (2) instances, where (1) 700HM IL-4 is increased where it should be black or green/decreased. Why was IL4 increased in HM where the dosage was better matched to the receptor quantity? Was there a greater tendency to enter M2 mode and metabolize fiber even despite the fact that both interferon gamma and CCL3 were both screaming that the Macrophages were in M1 mode, and this happened only when LRM was properly dosed?

And (2), there was also another discrepancy in the slight reduction in IL4 in the 350mg > 950 ms cT1 group. This should have been black or red like the other (2) 350 rectangles if it were to correlate. Why was it reduced/green? Why was IL4 reduced when only 350mg was given to patients who had severe fibrosis to begin with? With all this fibrosis, there was less of a tendency to maintain M2 mode? Maybe cause the loss in cT1 was -68.86ms p=0.009 and that it was that massive loss of fibrous tissue which led to the reduced IL-4, the reduced push or need to maintain M2 mode, despite the fact that Interferon Gamma and CCL3 were both saying the system is in M2. Maybe because the 350mg dose was so effective at that level that it brought cT1 so low, that there was less of a need to remain in the M2 mode.

I don't agree with the Magic which you describe. Leronlimab does not solely revert the Macrophages to M1, but rather it allows the Macrophages to operate where they should operate to reduce the disease and increase health. Leronlimab allows for the proper communication between the immune cells so that the decisions of the T cells and the T regs can be properly made without a confounding presence of RANTES around. Also, M2 is not an inflammatory state.

Quote:
This early IL-4 production rapidly converts resident macrophages into a population of cells that are programmed to promote wound healing;

Macrophages treated in vitro with IL-4 and/or IL-13 fail to present antigen to T cells, produce minimal amounts of pro-inflammatory cytokines and are less efficient than classically activated macrophages at producing toxic oxygen and nitrogen radicals, and at killing intra cellular pathogens. However, these cells secrete components of the extracellular matrix and therefore their primary function seems to be related to wound healing. These macrophages can also exert indirect regulatory effects on the immune response because the polyamines they produce can influence the production of cytokines and suppress the clonal expansion of neighbouring lymphocytes
This is ANTI-INFLAMMATORY.

When M2 is activated in a Macrophage, it is impossible for that Macrophage to perform in the M1 mode and vic versa. The Macrophage does 1 of 3 things only. It M1) kills/destroys, it M2) heals or it lies dormant in quiescence as Macrophage Regulator. When it kills and destroys, that is inflammatory. The healing part leans towards calming down while it rebuilds vasculature and lays down collagen and fibrotic tissue which leads to scarring. This is not inflammatory, The laying down of fiber is a means to reduce inflammation and swelling, otherwise, you would have bleeding gaps where the necrotic hepatocytes died with open wounds. The act of fibrosis is that of a healing role, but we have to undo that anyway and that is why I think the M2 mode is that of 2 functions, fibrogenesis and fibrous resorption. It is a give and take of the existing fibrous tissue. Add more and/or take away from.

With the proper dosing of leronlimab, the cytokines function appropriately to allow the appropriate time period for the Macrophages to remain in M2 mode to eradicate and metabolize the fiber if it exists and the time to remain in M1 to address the sick hepatocytes if they call, which subsequently addresses the steatosis and tends to restore the liver back to health.

Leronlimab doesn't have any direct anti-inflammatory effects by increased RO, it induces reduced inflammation by effecting a healing response within the body, by permitting and allowing the proper cytokine signaling to get the job done without the confounding influence of RANTES disrupting the correct mechanism of action.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Supernova SPAC Lawsuit: Settlement Proposed, $3M on Table

Updated Category News Views 2

Legal Clouds Over Supernova's SPAC Adventure Alright, folks, buckle up, because whenever you mix SPACs and lawsuits, you're in for a roller coaster. Supernova Partners Acquisition Company, Inc. stands right at the heart of a class action lawsuit, and it's been cooking ever since the court in Delaware gave it a nudge forward. Settlement Talk: What's on the Table? So here's...

Continue Reading
DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Updated Category News Views 0

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

Continue Reading
Universal Music Wraps €250M Share Buyback Plan

Updated Category News Views 1

Universal's Encore Performance in the Markets Universal Music Group (EURONEXT: UMG), the behemoth in music-based entertainment, just wrapped up its €250 million share buyback program. Talk about a grand finale! In a week’s worth of maneuvering from August 31 to September 4, they snagged 294,340 of their own shares, all for the pretty price of €14.65 a pop. Grand...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 5

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
EQT Wraps Up Share Buyback with 4.3M Shares Repurchased

Updated Category News Views 0

EQT's Bold Buyback: Crunching the Numbers Alright, let's peel back the curtain on EQT's latest maneuver—finishing up their share buyback program, all neat and tidy for 2026. They nailed down 707,203 of their own shares just in the first week of September, part of a grand total of 4,368,899 snatched up in the entire effort. That's a whopping SEK 1.448 billion invested in...

Continue Reading
Cultural Convergence: Ordos Event Captivates Global Visitors

Updated Category News Views 0

Ordos: Where Cultures Connect Seamlessly Spanning continents and cultures, the recent 'Warm City' event in Ordos, Inner Mongolia, drew international attention like bees to honey. Now, if you're thinking this is just another cultural shindig, think again. François Tchiegue, an ambassador of China-Africa cultural exchanges, described it best when he noted how the morin...

Continue Reading
Sky Labs' CART Monitor Advances BP Monitoring Tech

Updated Category News Views 1

Cuffless BP Monitoring: Changing the Game for AF and HF Ever thought a finger ring could revolutionize blood pressure monitoring? Well, welcome to the future—Sky Labs' ring-type CART monitor has just rocked the scene at the ESC Congress 2026 in Munich. This isn't sci-fi, folks; it's where health tech meets reality, and it's shaking the very foundations of how we manage...

Continue Reading
Multiconsult-Rejlers Merger Revs Up Nordic Market Power

Updated Category News Views 1

A New Powerhouse in the Nordic Consultancy Space September 7, 2026, will likely be etched into the annals of stock market moves, marking the day two titans, Multiconsult and Rejlers, decided to tie the knot. This isn't your average merger. We're talking about a calculated Pan-Nordic push that's been building, and now, well, it's paying off with a potential powerhouse of...

Continue Reading
Coastal Property Realities: A Deep Dive into Ownership

Updated Category News Views 2

Buying Coastal Property: A Balancing Act Ah, the dream of owning a piece of the beach in sunny South Florida. It sounds glamorous—something to brag about at the next family gathering. But let me tell you, diving into coastal property ownership isn't just about sipping cocktails by the ocean. It's about handling a fair share of headaches most folks don't anticipate....

Continue Reading
CME Group Smashes FX Open Interest Record Again

Updated Category News Views 2

Shattering Records: CME Group's Latest Milestone Well, here's a juicy nugget for your investment playbook. On September 4, 2026, CME Group proved, once again, why they're the big dog in the derivatives yard, announcing a new record in FX open interest—4,410,167 contracts! This tops the previous mark of 4,269,622 contracts set just a few months back. The futures and...

Continue Reading

Top 5 Most Recently Viewed Articles

Hyra Network Showcases Sovereign AI Vision at TOKEN2049 Event

Updated Category News Views 313

Hyra Network Shines at TOKEN2049 with Sovereign AI Vision Hyra Network has successfully showcased its vision for Sovereign AI at TOKEN2049 Singapore, capturing the attention of the global cryptocurrency community. This decentralized AI infrastructure project has made remarkable strides, positioning itself as a leader in the digital space. Achievements Highlighted at...

Continue Reading
SolarEdge and Canadian Solar: Navigating a Changing Market Landscape

Updated Category News Views 180

SolarEdge's Upward Revision and Future Prospects Goldman Sachs analyst Brian Lee has made significant revisions to the ratings of key residential solar stocks, revealing insights into the current market dynamics. The analyst points out a growing disconnect between mid-to-long-term fundamentals and stock valuations for solar and storage equities as we approach the next few...

Continue Reading
Root, Inc. Engages Investors With Upcoming Q3 Financial Call

Updated Category News Views 59

Root, Inc. Plans Conference Call for Q3 Financial Discussion Root, Inc. (NASDAQ: ROOT), known for its innovative approach in the insurance sector, is gearing up to hold a significant conference call aimed at discussing its financial performance for the third quarter. This call is scheduled for October 30, providing an opportunity for investors and stakeholders to gain...

Continue Reading
EMQ and Volt Active Data Join Forces for Advanced IoT Solutions

Updated Category News Views 176

Partnership Revolutionizes IoT Automation This collaboration creates a comprehensive device-to-decision platform for mission-critical IoT automation. EMQ, recognized as a global leader in MQTT messaging and IoT connectivity, has formed an innovative partnership with Volt Active Data, a leading real-time data platform. This alliance aims to empower enterprises by...

Continue Reading
GitLab Investors Urged to Evaluate Losses Promptly for Action

Updated Category News Views 48

Investors of GitLab Are Urged to Take Action Now In a significant development for shareholders of GitLab Inc. (NASDAQ: GTLB), the law firm Faruqi & Faruqi, LLP is investigating claims regarding potential financial losses among investors. Individuals who have incurred losses exceeding $100,000 in GitLab are especially encouraged to reach out to the firm for a comprehensive...

Continue Reading